The low survival rate among patients with advanced thyroid cancer implies a dearth of effective treatment strategies. Research on advanced thyroid cancer has focused on targeted drugs, while neglecting the prognostic prediction for patients with advanced thyroid cancer who are undergoing surgical treatment. Consequently, further investigation into the prognostic implications of surgery for patients with advanced thyroid cancer is of great significance.
Methods
This study retrieved and screened all stage IV thyroid cancer patients between 2010 and 2020 in the SEER database, and finally included 670 patients in the study. Independent risk factors, which were used to develop a nomogram model predicting prognosis, were screened using univariate and multivariate Cox regression analyses. Furthermore, the log-rank test was used to compare differences in the Kaplan-Meier curves of overall survival (OS) and cancer-specific death (CSS) in different risk factor groups.
Result
Survival analysis was performed based on the OS and TCSS of the surgical and non-surgical groups, and the Kaplan-Meier curves were statistically significant. Cox multivariate analysis showed statistical significance in grade, T stage, surgery, and radiotherapy. When statistically significant variables were incorporated into the construction of the prediction model, the C-index of the training group was 0.857, and the areas under the ROC curve of the modeling group were 0.927, 0.925, and 0.919, respectively. The areas under the ROC curve for the validation group were 0.934, 0.937, and 0.944, respectively. The calibration curves and DCA curves showed excellent prediction effect in the prediction model.
Conclusion
The prognostic prediction model established in this study demonstrated higher predictive accuracy.
SungHFerlayJSiegelRL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CACancer J Clin. 2021;71(2):209-249.
2.
PizzatoMLiMVignatJ, et al.The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates the incidence and mortality rates of thyroid cancer in 2020. Lancet Diabetes Endocrinol. 2022;10:264-272.
3.
NowellPC. Clonal evolution of tumor cell populations. Science. 1976;194(4260):23-28.
4.
ShobabLGomes-LimaCZeymoA, et al.Clinical, pathological, and molecular profiling of radioactive iodine-refractory differentiated thyroid cancer. Thyroid. 2019;29(9):1262-1268.
5.
WangWMengCOuyangQXieJLiX. Magnesemia is an independent risk factor for hypocalcemia following thyroidectomy. Cancer Manag Res. 2019;11:8135-8144.
6.
KimHParkSYJungJ, et al.Improved survival after the early detection of asymptomatic distant metastasis in patients with thyroid cancer. Sci Rep. 2019;9(1):18745.
7.
WangWDingYJiangWLiX. Can cervical lymph node metastasis increase the risk of distant metastasis in papillary thyroid carcinoma?Front Endocrinol. 2022;13:917794.
8.
LinBMaHMaM, et al.Incidence and survival analysis for anaplastic thyroid cancer: SEER database analysis. Am J Transl Res. 2019;11(9):5888e96.
9.
WuMHLeeYYLuYLLinSF. Risk factors and prognosis for metastatic follicular thyroid cancer. Front Endocrinol. 2022;13:791826.
10.
Risk factors and outcomes of postoperative recurrent well-differentiated thyroid cancer: a single institution's 15-Year experience.
11.
LahaDNilubolNBoufraqechM. New therapies for advanced thyroid cancer. Front Endocrinol. 2020;11:82.
12.
SiegelRLMillerKDJemalA. Cancer statistics, 2019[J]. CA Cancer J Clin. 2019;69(1):7-34.
13.
HarrellFECaliffRMPryorDBLeeKLRosatiRA. Evaluation of yield of medical tests[J]. JAMA. 1982;247(18):2543-2546.
14.
HosmerDWHosmerTLe CessieSLemeshowS. Comparison of goodness-of-fit tests for the logistic regression model[J]. Stat Med. 1997;16(9):965-980.
15.
VickersAJElkinB. Decision curve analysis: a novel method for evaluating prediction models[J]. Med Decis Mak. 2006;26(6):565-574.
16.
National Cancer Institute; Bethesda, M. SEER Cancer Stat Facts: Thyroid Cancer. Bethesda, MD, USA: National Cancer Institute; 2022.
17.
Eustatia-RuttenCFCorssmitEPBiermaszNRPereiraAMRomijnJASmitJW. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006;91(1):313-319.
18.
VolanteMLandolfiSChiusaL, et al.Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. Cancer. 2004;100:950-957.
19.
RaoSNSmallridgeRC. Anaplastic thyroid cancer: an update. Best Pract Res Clin Endocrinol Metab. 2023;37(1):101678.
20.
BibleKCKebebewEBrierleyJ, et al.2021 American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2021;31(3):337-386.
21.
NguyenXVRoy ChoudhuryKTesslerFNHoangJK. Effect of tumor size on risk of metastatic disease and survival for thyroid cancer: implications for biopsy guidelines. Thyroid. 2018;28(3):295-300.
22.
KebebewEGreenspanFSClarkOHWoeberKAGrunwellJ. Extent of disease and practice patterns for medullary thyroid cancer. J Am Coll Surg. 2005;200(6):890-896.
23.
van VelsenEFSVisserWEStegengaMT, et al.Finding the optimal age cutoff for the UICC/AJCC TNM staging system in patients with papillary or follicular thyroid cancer. Thyroid. 2021;31(7):1041-1049.
24.
RossiEDMehrotraSKilicAI, et al.Noninvasive follicular thyroid neoplasm with papillary-like nuclear features in the pediatric age group. Cancer Cytopathol. 2018;126(1):27-35.
25.
HaymartMR. Understanding the relationship between age and thyroid cancer. Oncologist. 2009;14(3):216-221.
26.
WangWShenCYangZ. Nomogram individually predicts the risk for distant metastasis and prognosis value in female differentiated thyroid cancer patients: a SEER-based study. Front Oncol. 2022;12:800639.
27.
CuiHWangRZhaoXWangSShiXSangJ. Development and validation of a nomogram for predicting the early death of anaplastic thyroid cancer: a SEER population-based study. J Cancer Res Clin Oncol. 2023;149(17):16001-16013.
28.
OliinykDAugustinTRauchJ, et al.Role of surgery to the primary tumor in metastatic anaplastic thyroid carcinoma: pooled analysis and SEER-based study. J Cancer Res Clin Oncol. 2023;149(7):3527-3547.
29.
YangZFloresJKatzSNathanCAMehtaV. Comparison of survival outcomes following postsurgical radioactive iodine versus external beam radiation in stage IV differentiated thyroid carcinoma. Thyroid. 2017;27(7):944-952.
30.
HamiltonSNTranEBertheletEWuJ. The role of external beam radiation therapy in well-differentiated thyroid cancer. Expert Rev Anticancer Ther. 2017;17(10):905-910.
31.
TerezakisSALeeKSGhosseinRA, et al.Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-kettering cancer center experience. Int J Radiat Oncol Biol Phys. 2009;73(3):795-801.
32.
RoukozCGregoireV. Indications of external beams radiation for thyroid cancer. Curr Opin Otolaryngol Head Neck Surg. 2022;30(2):137-144.
33.
FusseyJMCrunkhornRTedlaMWeickertMOMehannaH. External beam radiotherapy in differentiated thyroid carcinoma: a systematic review. Head Neck. 2016;38(Suppl 1):E2297-E2305.
34.
AlberoALopézJETorresAde la CruzLMartínT. Effectiveness of chemotherapy in advanced differentiated thyroid cancer: a systematic review. Endocr Relat Cancer. 2016;23(2):R71-R84.
35.
LiYZhangHCaoY, et al.Establishment and verification of the first prognostic nomograms in locally advanced thyroid cancer based on the analysis of clinical and follow-up information on 2396 patients. Heliyon. 2024;10(10):e31454.
36.
HaugenBRAlexanderEKBibleKC, et al.2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1-133.
37.
PappaTAhmadiSMarquseeE, et al.Oncogenic mutations in PI3K/AKT/mTOR pathway effectors associate with worse prognosis in BRAFV600E -Driven papillary thyroid cancer patients. Clin Cancer Res. 2021;27(15):4256-4264.
38.
BallDWJinNRosenDM, et al.Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activatedprotein kinase kinase 1/2 inhibitor AZD(6244). J Clin Endocrinol Metab. 2007;92:4712-4718.
39.
LeboeufRBaumgartnerJEBenezraM, et al.BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab. 2008;93:2194-2201.
40.
HannaGJBusaidyNLChauNG, et al.Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study. Clin Cancer Res. 2018;24:1546-1553.
41.
SchneiderTCde WitDLinksTP, et al.Everolimus in patients with advanced follicular-derived thyroid cancer:results of a phase II clinical trial. J Clin Endocrinol Metab. 2017;102:698-707.
